A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia

Anne‐Marie Chaftari(The University of Texas MD Anderson Cancer Center), Issam Raad(Missouri Department of Agriculture), Patrick Chaftari(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center), Ray Hachem(The University of Texas MD Anderson Cancer Center), Teny M. John(The University of Texas MD Anderson Cancer Center), Hiba Dagher(The University of Texas MD Anderson Cancer Center), Andrea Haddad(The University of Texas MD Anderson Cancer Center), Patricia Mulanovich(The University of Texas MD Anderson Cancer Center), Shahnoor Alii(The University of Texas MD Anderson Cancer Center), Ann Philip(The University of Texas MD Anderson Cancer Center), Rita Wilson Dib(The University of Texas MD Anderson Cancer Center), Peter Lamie(The University of Texas MD Anderson Cancer Center), Ying Jiang(The University of Texas MD Anderson Cancer Center)
Journal of Antimicrobial Chemotherapy
July 12, 2024
Cited by 11


Related Papers